4-溴靛红酸酐 | 76561-16-5

• 物质功能分类: 化学试剂 - 有机试剂 - 羧酸酐
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 4-溴靛红酸酐
• 中文别名: 7-溴-2H-3,1-苯并恶嗪-2,4(1H)-二酮
• 英文名称: 7-bromo-1H-benzo[d][1,3]oxazine-2,4-dione
• 英文别名: 4-bromoisatoic anhydride；7-bromo-2H-3,1-benzoxazine-2,4(1H)-dione；7-bromo-2H-benzo[d][1,3]oxazine-2,4(1H)-dione；7-bromo-1,2-dihydro-3,1-4H-benzoxazine-2,4-dione；7-bromo-1H-3,1-benzoxazine-2,4-dione
• CAS: 76561-16-5
• 化学式: C₈H₄BrNO₃
• mdl: MFCD11113115
• 分子量: 242.029
• InChiKey: PDGHWWQDMPEMKS-UHFFFAOYSA-N

物化性质

• 密度：
  1.826

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H315,H317,H319
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromoisatoic anhydride
Synonyms: 7-Bromo-1H-benzo[d][1,3]oxazine-2,4-dione

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromoisatoic anhydride
CAS number: 76561-16-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H4BrNO3
Molecular weight: 242.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴靛红酸酐 在 碳酸氢铵 作用下， 以 1,4-二氧六环 为溶剂， 生成 2-氨基-4-溴苯甲酰胺
  参考文献：
  名称：

  1,2,3-Benzotriazin-4-one衍生物对根结线虫的合成及杀线虫活性

  摘要：

  通过3-溴烷基-1,2,3-苯并三嗪-4-酮与2-氰基氨基-4-氧噻唑烷的钾盐反应，合成了一系列新的1,2,3-苯并三嗪-4-酮衍生物。碘化钾的存在。杀线虫试验在体内表明，它们中的一些表现出对所造成的黄瓜根结线虫病良好的防治效果南方根结线虫以10.0毫克的L的浓度，最高可达100％-1，表明1,2,3-苯并三-4-one衍生物可能是新型杀线虫剂的潜力。杀线虫活性受分子中取代基类型，取代位置和接头长度的组合影响。浓度为5.0和1.0 mg L –1时的抑制率数据还提供了具有高抑制活性的化合物。当在体外测试时，没有一个对隐孢霉菌有直接抑制作用。体内和体外数据之间显着差异的研究正在进行中。

  DOI：

  10.1021/acs.jafc.5b01762
• 作为产物：
  描述：

  6-溴靛红 在 二苯基二硒醚 、 双氧水 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 8.0h， 以78%的产率得到4-溴靛红酸酐
  参考文献：
  名称：

  Recyclable (PhSe)₂-catalyzed selective oxidation of isatin by H₂O₂: a practical and waste-free access to isatoic anhydride under mild and neutral conditions

  摘要：

  一种实用且无废物的异酞酸酐合成方法被报道。该方法的特点是通过过滤进行简单的分离程序，有助于直接回收和重复使用有机硒催化剂和溶剂。

  DOI：

  10.1039/c5cy01030f

文献信息

• 喹啉酮类化合物及其在药物中应用
  申请人：广东东阳光药业有限公司

  公开号：CN105384687B

  公开（公告）日：2018-05-01

  本发明涉及喹啉酮类化合物及其在药物中的应用，具体涉及一种新的喹啉酮类化合物及其药物组合物，以及所述化合物或所述药物组合物在制备药物中的用途；所述药物用于防护、处理、治疗或减轻患者HIF相关和/或EPO相关的疾病，其中，所述HIF相关和/或EPO相关的疾病包括贫血、血管疾病、心肌局部缺血、代谢障碍或伤口愈合等。
• Synthesis of 123I-Labelled Analogues of Imidazobenzodiazepine Receptor Ligands.
  作者：Meredith E. McPhee、Andrew G. Katsifis、Filomena Mattner、Damon D. Ridley

  DOI：10.1071/ch99135

  日期：——

  Reaction of bromo- or iodo-substituted isatoic anhydrides with N-methylglycine, L-proline or D-proline afforded bromo- or iodo-substituted 1,4-benzodiazepinediones which on condensation with ethyl or t-butyl isocyanoacetates gave ethyl or t-butyl bromo- or iodo-imidazobenzodiazepine carboxylates. These aryl halides were converted into the corresponding tributylstannanes with bis(tributyltin) in the presence of (triphenylphosphine)palladium(0), and the stannanes were treated with sodium (123I)iodide in the presence of chloramine-Tto give the required 123I- labelled analogues of the imidazobenzodiazepine receptor ligands flumazenil and bretazenil.

  溴代或碘代异丁烯酸酐与 N-甲基甘氨酸、L-脯氨酸或 D-脯氨酸反应，得到溴代或碘代的 1,4-苯并二氮杂环庚二酮。 或碘代的 1,4-苯并二氮杂环庚二酮，在与乙基或叔丁基异氰基乙酸酯缩合后 异氰基乙酸乙酯或异氰基乙酸叔丁酯缩合后，得到溴代或碘代咪唑苯并 碘咪唑并二氮杂卓羧酸酯。这些芳基卤化物 在（三苯基膦）存在下，用双（三丁基锡）将这些芳基卤化物转化为相应的三丁基锡烷。 三苯基膦）钯（0）的存在下，用双（三丁基锡）将这些芳基卤化物转化为相应的三丁基锡烷，然后用 在氯胺-T 的存在下，用（123I）碘化钠处理锡烷，得到所需的 123I 标记。 得到所需的 123I 标记的类似物 咪唑苯并二氮杂卓受体配体氟马西尼和溴他西尼。
• Morpholinylquinazolines
  申请人：Mederski Werner

  公开号：US20130012489A1

  公开（公告）日：2013-01-10

  The invention relates to compounds of the formulae (I), (II) and (III) in which R1, R2, R3, R4, Y, W 1 , W 2 , L, A, Alk, Cyc, Ar, Het 1 , Het 2 , Hal and n have the meaning indicated in claim 1 , and/or physiologically acceptable salts, tautomers and stereo-isomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formulae (II) and (III) and optionally conversion of a base or acid of the compounds of the formula (I) into one of their salts.

  该发明涉及以下式(I)、(II)和(III)的化合物： 其中R1、R2、R3、R4、Y、W1、W2、L、A、Alk、Cyc、Ar、Het1、Het2、Hal和n具有权利要求书中所示的含义，以及/或其生理上可接受的盐、互变异构体和立体异构体，包括所有比例的混合物。式(I)的化合物可用于抑制丝氨酸/苏氨酸蛋白激酶，并使癌细胞对抗癌药物和/或电离辐射敏感。该发明还涉及在放射治疗和/或抗癌药物的联合下使用式(I)的化合物在癌症、肿瘤、转移瘤或血管生成紊乱的预防、治疗或进展控制中。此外，该发明还涉及通过将式(II)和(III)的化合物反应，并可选地将式(I)的化合物的碱或酸转化为它们的盐之一来制备式(I)的化合物的方法。
• Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1-a]quinazoline-5,11‑dione derivatives: An unexpected observation
  作者：G Dhananjaya、Rapolu Venkateshwarlu、Naresh Kumar Reddy Dinne、Avula Mahesh Kumar、Ramamohan Mekala、Venkateswara Rao Anna、Ravikumar Kapavarapu、Manojit Pal

  DOI：10.1016/j.molstruc.2021.131922

  日期：2022.2

  acidic catalyst for the synthesis of isoindolo[2,1-a]quinazoline-5,11-dione derivatives under green conditions. Thus the Wang-OSO3H catalyzed MCR of isatoic anhydride, 2-formylbenzoic acid and various amines in pure water afforded a range of desired product in good to excellent (86-94%) yield. The methodology can be performed under open air and is amenable for scale-up synthesis. The catalyst can be recovered

  磺酸官能化的 Wang 树脂 (Wang-OSO 3 H) 被探索作为一种聚合和可回收的酸性催化剂，用于在绿色条件下合成异吲哚并 [ 2,1- a ] 喹唑啉-5,11-二酮衍生物。因此，Wang-OSO 3H 催化的靛红酸酐、2-甲酰基苯甲酸和各种胺在纯水中的 MCR 以良好至极好的 (86-94%) 产率提供了一系列所需产物。该方法可以在露天下进行，并且适合放大合成。催化剂可多次回收和循环使用，其催化活性没有明显损失。在一种情况下观察到的 2-(1-羟基-3-氧代异吲哚啉-2-基)苯甲酰胺衍生物的意外形成可能允许通过使用适当的胺从相同的 MCR 获得此类杂环。计算机评估表明，已知的 TNF-α 抑制剂化合物4j可能是 SARS-CoV-2 的潜在配体，它通过其 OMe 和两个 C=O 基团与其形成 H 键。
• [EN] 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS DE 1,3,4-OXADIAZOLE HOMOPHTALIMIDE UTILISÉS COMME INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2020240493A1

  公开（公告）日：2020-12-03

  The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a medicinal use thereof, and a method for preparing the same. The novel compounds according to the present invention, stereoisomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; endocrinopathy; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, or chromosomal aberration.

  本发明涉及具有组蛋白去乙酰化酶6（HDAC6）抑制活性的新化合物，其立体异构体或其药学上可接受的盐，其药用用途以及其制备方法。根据本发明的新化合物，其立体异构体或其药学上可接受的盐具有组蛋白去乙酰化酶6（HDAC6）抑制活性，并且在预防或治疗与HDAC6相关的疾病方面具有有效性，包括传染病；肿瘤；内分泌病；营养和代谢疾病；精神和行为障碍；神经系统疾病；眼部和眼附器疾病；循环系统疾病；呼吸系统疾病；消化系统疾病；皮肤和皮下组织疾病；肌肉骨骼系统和结缔组织疾病；以及畸形或变形，或染色体异常。